Beam Therapeutics Inc (NASDAQ: BEAM) is -19.64% lower on its value in year-to-date trading and has touched a low of $13.52 and a high of $35.25 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BEAM stock was last observed hovering at around $19.71 in the last trading session, with the day’s gains setting it 0.22%.
Currently trading at $19.93, the stock is 13.63% and -11.05% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.08 million and changing 1.12% at the moment leaves the stock -20.45% off its SMA200. BEAM registered -6.78% loss for a year compared to 6-month loss of -7.52%. The firm has a 50-day simple moving average (SMA 50) of $22.4048 and a 200-day simple moving average (SMA200) of $25.0523.
The stock witnessed a 2.05% gain in the last 1 month and extending the period to 3 months gives it a -23.08%, and is 0.30% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.40% over the week and 9.54% over the month.
Beam Therapeutics Inc (BEAM) has around 483 employees, a market worth around $2.00B and $63.52M in sales. Profit margin for the company is -593.13%. Distance from 52-week low is 47.36% and -43.46% from its 52-week high. The company has generated returns on investments over the last 12 months (-42.74%).
with sales reaching $14.68M over the same period.The EPS is expected to shrink by -3.23% this year, but quarterly earnings will post 0.27% year-over-year. Quarterly sales are estimated to grow 98.18% in year-over-year returns.
340.0 institutions hold shares in Beam Therapeutics Inc (BEAM), with institutional investors hold 79.80% of the company’s shares. The shares outstanding are 100.56M, and float is at 85.97M with Short Float at 21.90%. Institutions hold 78.78% of the Float.
The top institutional shareholder in the company is FARALLON CAPITAL MANAGEMENT LLC with over 7.91 million shares valued at $185.4 million. The investor’s holdings represent 9.6135 of the BEAM Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 7.9 million shares valued at $185.11 million to account for 9.598 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 7.63 million shares representing 9.2749 and valued at over $178.87 million, while ARK INVESTMENT MANAGEMENT LLC holds 9.2649 of the shares totaling 7.63 million with a market value of $178.68 million.
Beam Therapeutics Inc (BEAM) Insider Activity
The most recent transaction is an insider sale by Bellon Christine, the company’s Chief Legal Officer. SEC filings show that Bellon Christine sold 5,674 shares of the company’s common stock on Apr 01 ’25 at a price of $18.35 per share for a total of $0.1 million. Following the sale, the insider now owns 0.12 million shares.
Beam Therapeutics Inc disclosed in a document filed with the SEC on Apr 01 ’25 that Evans John M. (CEO) sold a total of 30,663 shares of the company’s common stock. The trade occurred on Apr 01 ’25 and was made at $18.35 per share for $0.56 million. Following the transaction, the insider now directly holds 0.99 million shares of the BEAM stock.
Still, SEC filings show that on Apr 01 ’25, Ciaramella Giuseppe (President) disposed off 7,434 shares at an average price of $18.35 for $0.14 million. The insider now directly holds 190,216 shares of Beam Therapeutics Inc (BEAM).
